Crescent Biopharma, Inc. (CBIO)
$12.91-10.72%Close
SELLCRISIS · day 20
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $356M
- Beta
- 1.26
- P/E (TTM)
- -1.70
- Short % float
- 22.40%
- Days to cover
- 6.8
- SI change
- +40.2%
- 1W
- -4.86%
- 1M
- -34.40%
- vs SPY 1W
- -4.73%
- vs SPY 1M
- -36.91%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 2
- VALUE
- 16
- GROWTH
- 19
- GARP
- 4
- TYPE
- Value / Recovery
Composite of Value · Growth · GARP
ROIC-58.7%
REV YoY-
ROE-97.8%
EPS YoY-
ROA-89.2%
GROSS100
OP-1418
NET-1372
[VALUATION]
P/E TTM-1.70
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B2.41
P/FCF-
EV/EBITDA-1.90
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.88
ALTMAN Z-
CURR RATIO9.66
ND/EBITDA-
BETA1.26
Company news
FAQ
- What is LOPJLB’s current signal on CBIO?
- LOPJLB’s latest quantitative signal on Crescent Biopharma, Inc. (CBIO) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is CBIO in?
- Crescent Biopharma, Inc. (CBIO) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Crescent Biopharma, Inc. (CBIO) do?
- Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a …